Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Alaunos Therapeutics Inc (TCRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: TCRT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $1.75
Year Target Price $1.75
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.94% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.41M USD | Price to earnings Ratio - | 1Y Target Price 1.75 |
Price to earnings Ratio - | 1Y Target Price 1.75 | ||
Volume (30-day avg) - | Beta -1.09 | 52 Weeks Range 1.31 - 7.00 | Updated Date 06/29/2025 |
52 Weeks Range 1.31 - 7.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -54600% |
Management Effectiveness
Return on Assets (TTM) -63.78% | Return on Equity (TTM) -139.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2348742 | Price to Sales(TTM) 764.61 |
Enterprise Value 2348742 | Price to Sales(TTM) 764.61 | ||
Enterprise Value to Revenue 213.52 | Enterprise Value to EBITDA -3.55 | Shares Outstanding 1639520 | Shares Floating 1557545 |
Shares Outstanding 1639520 | Shares Floating 1557545 | ||
Percent Insiders 9.18 | Percent Institutions 3.59 |
Analyst Ratings
Rating 3 | Target Price 1.75 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alaunos Therapeutics Inc
Company Overview
History and Background
Alaunos Therapeutics, Inc. (formerly Ziopharm Oncology) is a biopharmaceutical company focused on developing T-cell receptor (TCR) therapies for solid tumors. Founded in 2003, they've shifted focus towards TCR-T cell therapies.
Core Business Areas
- TCR-T Cell Therapy Development: Alaunos develops TCR-T cell therapies targeting solid tumors. They engineer a patient's T cells to recognize and kill cancer cells expressing specific tumor-associated antigens.
Leadership and Structure
Kevin S. Boyle, Sr. is the Chief Executive Officer. The company has a board of directors and various management teams overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- ALD-501: Alaunos's lead TCR-T cell therapy targeting MAGE-A4 for solid tumors. Currently in clinical trials. Market share is currently 0% as it's not yet commercialized. Competitors include companies developing cell therapies for solid tumors, such as Adaptimmune and Iovance Biotherapeutics.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in gene editing and immunotherapy. Significant unmet need remains for effective treatments for solid tumors.
Positioning
Alaunos is positioned as a clinical-stage biopharmaceutical company focused on TCR-T cell therapies for solid tumors. Their competitive advantage lies in their specific TCR technology and target selection.
Total Addressable Market (TAM)
The overall oncology market is estimated to be hundreds of billions of dollars. The cell therapy segment specifically is expected to reach tens of billions in the next decade. Alaunos is positioned to capture a portion of this market with successful therapies.
Upturn SWOT Analysis
Strengths
- Proprietary TCR-T cell therapy platform
- Focus on solid tumors with high unmet need
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Limited product pipeline
Opportunities
- Positive clinical trial data
- Strategic partnerships
- Expansion of TCR-T cell therapy platform
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- ADAP
- IOVA
- NK
- CRSP
Competitive Landscape
Alaunos faces significant competition from established pharmaceutical companies and other biotech firms developing cell therapies. Their competitive advantage depends on the efficacy and safety of their TCR-T cell therapies compared to existing and emerging treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the developmental stage of the company. Growth prospects are tied to the success of clinical trials.
Future Projections: Future growth projections are highly dependent on the success of ALD-501. Analyst estimates vary widely, but positive clinical trial results could lead to significant revenue potential.
Recent Initiatives: Recent initiatives include focusing on the ALD-501 program, optimizing the TCR-T cell therapy platform, and seeking potential partnerships.
Summary
Alaunos Therapeutics is a high-risk, high-reward clinical-stage company focused on novel cancer treatments. They are working on novel TCR-T cell therapies to treat solid tumors. The company is still years away from generating product revenue and will require further capital. Success of their clinical trials will make or break the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alaunos Therapeutics Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2005-08-24 | Interim CEO & Director Mr. Dale Curtis Hogue Jr. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.alaunos.com |
Full time employees 1 | Website https://www.alaunos.com | ||
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.